Advanced Uterine Carcinosarcoma With Fatal Suspected Pulmonary Embolism in a Resource‐Limited Setting: A Rare Case Report Authors: John Lugata, Onesmo Mrosso, Tecla Lyamuya, Jasmine E Arrington, Elizabeth Skinner, Bariki Mchome, Eusebious Maro, Alex Mremi Published: 2026 ABSTRACT ABSTRACTUterine carcinosarcoma (UCS), also known as malignant mixed Müllerian tumor (MMMT), is a biphasic neoplasm characterized by the presence of carcinomatous (epithelial) and sarcomatous (stromal tissue) elements. It frequently presents at an advanced stage and can mimic primary ovarian carcinoma on clinical and radiological evaluation, particularly when diagnosed after hysterectomy for presumed benign disease. To our knowledge, this represents one of the few reported cases of metastatic UCS from Sub‐Saharan Africa. We report a case of advanced UCS in a 59‐year‐old postmenopausal woman who presented to a tertiary referral center in Northern Tanzania with a 6‐month history of gradual‐onset, progressive abdominal pain and distension. Physical examination revealed pallor, tachycardia, bilateral lower limb edema, and a large, irregular abdominopelvic mass. Contrast‐enhanced CT scan demonstrated a massive heterogeneously enhancing abdominopelvic mass (24 × 22 × 12 cm) with central necrosis, diffuse peritoneal carcinomatosis, omental caking, and diaphragmatic deposits. Findings were also notable for hepatic surface scalloping, multiple liver lesions, bulky necrotic retroperitoneal lymphadenopathy, moderate ascites, and innumerable bilateral pulmonary nodules, suggestive of advanced ovarian malignancy with widespread metastases. Histopathological review of the archived hysterectomy specimen and an umbilical wedge biopsy revealed a biphasic tumor with atypical glandular (carcinomatous) and spindle cell (sarcomatous) components, including frequent mitoses and necrosis. Immunohistochemistry (IHC) showed cytokeratin positivity in tumor cells within the carcinomatous component and desmin positivity in the sarcomatous component. Based on clinicopathological correlation, the diagnosis was confirmed as UCS, FIGO stage IVB. A multidisciplinary tumor board recommended neoadjuvant carboplatin and paclitaxel chemotherapy followed by interval cytoreductive surgery. Before treatment initiation, she developed progressive bilateral lower limb swelling suggestive of deep vein thrombosis. Empirical anticoagulation with unfractionated heparin was started. However, she suddenly deteriorated after an assisted fall, with loss of consciousness and respiratory distress. The presumed cause of death was highly suggestive of massive pulmonary embolism, although confirmatory imaging or postmortem examination was not available secondary to cancer‐associated venous thromboembolism (VTE), occurring in the setting of advanced stage IV uterine carcinosarcoma with extensive peritoneal, hepatic, and pulmonary metastases.Keywords: FIGO stage IVB, malignant mixed Müllerian tumor, massive pulmonary embolism, peritoneal carcinomatosis, resource‐limited setting, uterine carcinosarcoma Introduction Uterine carcinosarcoma (UCS), also known as malignant mixed Müllerian tumor (MMMT), is a rare, biphasic, and highly aggressive malignancy of the uterine corpus characterized by the presence of both malignant epithelial (carcinomatous) and mesenchymal (sarcomatous) components [1, 2]. Although UCS accounts for only 2%–5% of all endometrial malignancies, it is responsible for a disproportionately high number of uterine cancer‐related deaths due to its rapid progression, early metastatic spread, and poor response to therapy [1, 3]. UCS predominantly affects postmenopausal women, with a median age at diagnosis of 62–68 years [1, 4]. The incidence has been steadily increasing. In the United States, age‐adjusted incidence rates rose from 2.2 per 1,000,000 women in 2000 to 5.5 per 1,000,000 in 2016, with higher rates observed among Black women [4, 5]. Established risk factors include advanced age, obesity, nulliparity, prior pelvic radiation, and tamoxifen exposure; these overlap significantly with the risk factors for type II endometrial carcinoma [1, 6]. Clinically, patients often present at an advanced stage (FIGO III–IV) with symptoms such as postmenopausal bleeding, abdominal pain, distension, weight loss, altered bowel habits, and constitutional symptoms [1, 3]. Due to its strong propensity for peritoneal dissemination and elevated serum cancer antigens 125 (CA‐125) levels, UCS is frequently misdiagnosed preoperatively as advanced ovarian carcinoma or recurrent uterine fibroids, especially in women with a recent hysterectomy for presumed benign disease [3]. Radiologically, it typically appears as a large heterogeneous abdominopelvic mass with central necrosis, omental caking, ascites, peritoneal deposits, and distant metastases to lymph nodes, the liver, and lungs [1]. Histopathologically, UCS is now regarded as a metaplastic form of high‐grade endometrial carcinoma with monoclonal epithelial origin and sarcomatous differentiation rather than a true collision tumor [2, 7]. The epithelial component is most frequently high‐grade serous, endometrioid, or undifferentiated carcinoma, while the sarcomatous component may be homologous (e.g., endometrial stromal or leiomyosarcomatous) or heterologous (e.g., rhabdomyosarcoma, chondrosarcoma, or osteosarcoma) [1, 2]. Standard management of advanced UCS involves maximal cytoreductive surgery when feasible, combined with platinum‐based chemotherapy (most commonly carboplatin plus paclitaxel). Neoadjuvant chemotherapy is increasingly recommended for unresectable or stage IV disease [2, 8]. Despite multimodal therapy, the prognosis remains abysmal, with 5‐year overall survival for stage IV disease ranging from 0% to 15% and median survival often less than 12–18 months [1, 3]. Cancer‐associated venous thromboembolism (VTE), including deep vein thrombosis and fatal pulmonary embolism, is a frequent and life‐threatening complication in advanced UCS, driven by tumor‐induced hypercoagulability, venous stasis, and systemic inflammation [9, 10]. In this rare case, we present the diagnostic pitfalls, aggressive biological behavior, therapeutic challenges, and high risk of fatal thromboembolic events associated with advanced uterine carcinosarcoma in resource‐limited settings. Case History/Examination A 59‐year‐old woman (para 7 living 7) presented to our tertiary facility with a six‐month history of gradual‐onset, progressive abdominal pain and distension. She reported associated symptoms including bloating, early satiety, dyspepsia, nausea, occasional emesis, unintentional weight loss, back pain, changes in bowel habits, dyspareunia, dysuria, generalized weakness, dizziness, and palpitations. There was no history of fever, vaginal bleeding, or abnormal vaginal discharge. Her past medical history was significant for multiple prior admissions with similar complaints. Gynecological history revealed menarche at 16 years old and menopause at 45 years old. One year prior, she had undergone a total abdominal hysterectomy at a primary facility for symptomatic uterine fibroids. However, the surgical specimen was not submitted for histopathological evaluation. All seven pregnancies were delivered by spontaneous vaginal delivery without complications. On physical examination, the patient was pale and afebrile, with a blood pressure of 116/82 mmHg, pulse rate of 102 beats per minute, respiratory rate of 20 breaths per minute, and oxygen saturation of 98% on room air. She had finger clubbing and bilateral lower limb edema. Abdominal examination revealed marked distension with a prominent umbilical lesion (consistent with a Sister Mary Joseph nodule). The lesion was irregular, exophytic, and nodular, with areas of ulceration, necrosis, and slough, along with minimal seropurulent discharge. The surrounding skin showed hyperpigmentation and mild induration. A well‐healed midline infraumbilical surgical scar was noted, consistent with prior laparotomy (Figure 1). The abdomen was dull on percussion, and bowel sounds were reduced. Pelvic examination showed a well‐healed vaginal cuff with a firm palpable mass felt through the posterior vaginal wall. Digital rectal examination revealed a hard mass palpable on the anterior rectal wall. Examination of other systems was unremarkable. The abdomen demonstrating a markedly distended abdomen with a prominent umbilical mass. The lesion is irregular, exophytic, and nodular, with areas of ulceration, necrosis, and slough, along with minimal seropurulent discharge. A well‐healed midline infraumbilical surgical scar is noted, consistent with prior laparotomy. The findings are suggestive of a malignant umbilical metastasis (Sister Mary Joseph nodule) correlating with the patient's diagnosis of metastatic uterine carcinosarcoma. Differential Diagnosis, Investigations, and Treatment Given the patient's age at initial presentation, the leading differential diagnoses included ovarian cancer, uterine leiomyosarcoma, uterine sarcoma, and endometrial cancer. Laboratory investigations revealed mild anemia (hemoglobin 11.4 g/dL), while other hematological and biochemical parameters were within normal limits. Electrocardiogram (ECG) and echocardiogram (Echo) findings were normal. Chest X‐ray demonstrated obliteration of the right costophrenic and cardiophrenic angles, slightly reduced right lung volume, and a right apical subpleural nodule suggestive of possible metastasis. Serum cancer antigen 125 (CA‐125) was elevated at 110 U/mL (normal range: 0–35 U/mL), while carcinoembryonic antigen (CEA) was normal at 3 ng/mL (normal range: 0.00–5.093 ng/mL). Contrast‐enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis revealed a large, heterogeneously enhancing abdominopelvic mass measuring approximately 24 × 22 × 12 cm with areas of central necrosis (Figure 2A–C). The mass was relatively well‐defined, with severe compression and possible infiltration into the anterior rectal wall and distal sigmoid colon, abutting the posterior bladder wall. There was diffuse nodular peritoneal thickening with enhancing nodular deposits involving the diaphragm (the largest deposit abutting hepatic segments VII and VIII, causing scalloping of the liver margin). Prominent omental nodularity consistent with omental caking was noted. Additional findings included a right inguinal subcutaneous and muscular deposit (3 × 2 cm) from peritoneal seeding, multiple ill‐defined hypoenhancing liver lesions, enlarged necrotic lymph nodes in periportal, pericaval, mesenteric, and para‐aortic regions (the largest para‐aortic node measuring 5 × 4 cm), innumerable bilateral pulmonary nodules (the largest 2 × 2 cm in the right lower lobe), and moderate ascites. No bone lesions were identified. These features were highly suggestive of advanced ovarian malignancy with widespread peritoneal carcinomatosis, hepatic, and pulmonary metastases. Contrast‐enhanced computed tomography (CT) images of the abdomen and pelvis. (A) Axial view demonstrating a large, heterogeneously enhancing lesion within the liver (green arrow), suggestive of metastatic involvement. (B) Sagittal view showing a massive, well‐defined but heterogeneous abdominopelvic mass with areas of low attenuation consistent with necrosis (green arrow), causing significant mass effect on adjacent structures. (C) Coronal view confirming the extent of the large abdominopelvic mass (green arrow), occupying the lower abdomen and pelvis, with displacement and compression of surrounding bowel loops. The patient was admitted for palliative care. She received intravenous antibiotics, lactulose, and analgesia. The case was reviewed by a multidisciplinary tumor board consisting of gynecologists, medical oncologists, and pathologists. Considering the advanced disease, clinical findings, and resource limitations, a decision was made to obtain a tissue diagnosis via open wedge biopsy. Histopathological examination of the archived hysterectomy specimen revealed fragments of tissue infiltrated by a biphasic tumor composed of nests of atypical glands lined by hyperchromatic cells with enlarged nuclei and moderate amphophilic cytoplasm (carcinomatous component), surrounded by atypical spindle cells with hyperchromatic nuclei (sarcomatous component). The umbilical biopsy showed ulcerated skin infiltrated by a tumor exhibiting two distinct morphological patterns: Epithelial (carcinomatous) and mesenchymal (sarcomatous) components, with frequent mitoses and areas of necrosis (Figure 3A). (A) Histopathology of uterine carcinosarcoma showing a biphasic neoplasm composed of high‐grade epithelial (carcinomatous) and sarcomatous components. The carcinomatous component comprises atypical epithelial cells with pleomorphic nuclei and frequent mitoses, consistent with high‐grade serous carcinoma, while the sarcomatous component shows homologous oval‐to‐spindle cells consistent with high‐grade undifferentiated sarcoma (H&E, ×10). (B) Photomicrograph of uterine carcinosarcoma showing strong cytokeratin immunoexpression in tumor cells within the carcinomatous component (original magnification ×10). (C) Photomicrograph showing strong desmin immunoexpression in tumor cells within the sarcomatous component (original magnification ×10). Immunohistochemical analysis, performed with appropriate positive controls, demonstrated cytokeratin (AE1/AE3) immunoreactivity within the carcinomatous component, while the sarcomatous component showed desmin positivity (Figure 3B,C). Internal controls were satisfactory. The characteristic biphasic morphology, supported by the limited immunohistochemical panel, supported the diagnosis of UCS. Details of the specific antibody clones and staining platforms were unavailable in the archived pathology records, which represents a limitation. Although comprehensive molecular profiling was not performed, such testing may provide additional diagnostic, prognostic, and therapeutic insights through evaluation of commonly altered molecular pathways and genes, including TP53, PI3K/AKT/PTEN, and POLE alterations. Based on clinicopathological correlation, the final diagnosis was UCS, FIGO stage IVB. The tumor board recommended neoadjuvant chemotherapy (carboplatin and paclitaxel for 3–4 cycles) followed by interval cytoreductive surgery, in line with guidelines for advanced disease with an epithelial component. Bevacizumab and other targeted therapies could not be offered due to financial constraints and limited availability. Conclusion and Results (Outcome and Follow‐ Up) Prior to initiation of chemotherapy, the patient developed unilateral painful lower limb swelling that rapidly progressed to bilateral edema with warmth and tenderness, raising a strong clinical suspicion of deep vein thrombosis (DVT) secondary to malignancy‐associated hypercoagulability. Empirical therapeutic anticoagulation with unfractionated heparin (10,000 IU subcutaneously twice daily) was promptly initiated. Doppler ultrasound and CT pulmonary angiography were not performed due to financial limitations. Despite anticoagulation, the patient's condition suddenly deteriorated. While walking with assistance from a relative, she suffered a low‐impact fall, immediately followed by loss of consciousness and gasping respirations. The presumed cause of death was highly suggestive of massive pulmonary embolism, although confirmatory imaging or postmortem examination was not available. Discussion This report describes a rare case of UCS in a postmenopausal woman from northern Tanzania. Given the rarity of this malignancy worldwide, and particularly in our setting, the initial clinical differential diagnoses included uterine leiomyosarcoma, other uterine sarcomas, advanced ovarian carcinoma, and endometrial carcinoma. The definitive diagnosis was established following histopathological evaluation, which confirmed UCS. Based on this finding, a multidisciplinary team recommended neoadjuvant chemotherapy followed by interval cytoreductive surgery. This case highlights the uncommon nature of UCS, reviews similar cases reported in the literature, and underscores the diagnostic and management challenges encountered, especially in resource‐limited settings. UCS predominantly affects postmenopausal women, with a median age at diagnosis between 62 and 67 years old [11, 12]. Our patient, a postmenopausal woman at 59 years old, is consistent with this demographic pattern. The classical presentation of UCS is postmenopausal vaginal bleeding; however, advanced disease may manifest with nonspecific symptoms such as abdominal distension, pain, early satiety, and weight loss [13]. In contrast to many series where bleeding predominates, our patient presented with a six‐month history of gastrointestinal predominant symptoms. This picture closely mimicked advanced ovarian malignancy, a diagnostic challenge noted in several low‐resource cohorts where preoperative misdiagnosis as ovarian cancer occurs frequently [3]. Late‐stage (FIGO III–IV) presentation is common; over 60% of patients are diagnosed at advanced stages with extrauterine spread [2]. In a cohort study by Terblanche et al., more than 60% of patients presented with stage III–IV disease, largely due to delayed diagnosis [14]. This mirrors our case, which presented with FIGO stage IVB disease and widespread metastases. Imaging plays a central role in diagnosis and staging. Contrast‐enhanced CT characteristically revealed a large, heterogeneous abdominopelvic mass with central necrosis, irregular margins, omental caking, peritoneal nodular deposits, ascites, and distant metastases to lymph nodes, the liver, and lungs. These are features that frequently overlap with advanced ovarian carcinoma [15]. MRI typically shows heterogeneous T2 signal intensity, restricted diffusion, and variable enhancement, aiding differentiation from endometrioid adenocarcinoma in some studies [16]. CT imaging is particularly useful in detecting distant metastases, including pulmonary, hepatic, and peritoneal involvement [11]. Our patient's CT findings, elevated CA‐125, and normal CEA are consistent with patterns described in advanced UCS, which are also concerning for primary ovarian malignancy with peritoneal carcinomatosis upon initial impression. UCS is characterized by a biphasic histology comprising malignant epithelial (carcinomatous) and mesenchymal (sarcomatous) components and is now recognized as a monoclonal “metaplastic carcinoma” arising from a high‐grade epithelial precursor through epithelial–mesenchymal transition [7, 8]. Molecular studies reveal shared alterations between components, with TP53 mutations being the most frequent (62%–91%), followed by PIK3CA (20%–35%), PTEN, and others [17, 18, 19]. Ham et al. analyzed 51 UCS cases and found TP53 mutated in 88%, PIK3CA in 35%, and CCNE1 in 33%. Their findings support that the copy‐number‐high/p53‐abnormal TCGA subgroup is dominant while highlighting additional heterogeneity with potential therapeutic targets [19]. Hammer et al. similarly reported recurrent PIK3CA, PTEN, and TP53 mutations in POLE‐mutated subsets [20]. In our case, histopathological examination of the archived hysterectomy specimen and umbilical biopsy showed classical morphology consistent with recent literature [3, 12]. Comprehensive molecular testing was unavailable, consistent with challenges reported in low‐income countries where diagnosis relies primarily on morphology [3]. Management of advanced UCS is multimodal. Standard treatment for early‐stage disease includes total hysterectomy with bilateral salpingo‐oophorectomy and staging [1]. For stage IVB disease, neoadjuvant platinum‐based chemotherapy (carboplatin plus paclitaxel) followed by interval cytoreductive surgery is recommended when primary optimal resection is not feasible, with response rates of 54%–66% [7, 9]. Sağnıç et al. and other cohorts emphasize that the epithelial component guides systemic therapy selection, supporting carboplatin–paclitaxel as a standard regimen due to better tolerability than ifosfamide‐based combinations [9, 21]. Despite treatment advances, prognosis remains poor: Median overall survival is typically less than 2 years, with 5‐year survival for stage IV disease ranging from 0% to 20% (approximately 20% in advanced stages overall) [1, 12, 21]. Smyth et al. reported an overall 5‐year survival of approximately 46.6%, but markedly worse outcomes in advanced‐stage patients [12]. In our case, the multidisciplinary tumor board recommendation aligned with contemporary guidelines and the highest‐level evidence from GOG‐261. Objective response rates with this regimen in advanced UCS range from 54% to 66% in retrospective and phase II data, although complete responses are infrequent [9]. Unfortunately, our patient rapidly decompensated and died of suspected cancer‐associated VTE with pulmonary embolism prior to chemotherapy initiation. This highlights the aggressive disease course and narrow therapeutic window in stage IVB UCS. UCS carries a high VTE risk (cumulative incidence 8%–10% in some series) due to tumor procoagulant factors, inflammation, and stasis from large pelvic masses/ascites [10, 22]. Khorana et al. demonstrated that VTE is one of the leading causes of death in cancer patients [23]. In our case, the clinical presentation was highly suggestive of massive pulmonary embolism, although confirmatory imaging or postmortem examination was not available. Fatal pulmonary embolism can occur despite anticoagulation, as documented in multiple case reports and cohorts. Guidelines recommend indefinite therapeutic anticoagulation (preferably low‐molecular‐weight heparin or direct oral anticoagulants when appropriate) for cancer‐associated thrombosis with active malignancy [8]. Conclusion This case of a 59‐year‐old postmenopausal woman with widely metastatic UCS (FIGO stage IVB) one year after total abdominal hysterectomy for presumed symptomatic fibroids illustrates the formidable diagnostic and therapeutic challenges posed by this rare malignancy. The tumor's aggressive nature was demonstrated by extensive spread, including liver and lung involvement. This case further emphasizes the critical role of histopathological evaluation in establishing a definitive diagnosis, particularly in settings where clinical and radiologic findings are inconclusive. The rapid progression and fatal outcome in this patient highlight the poor prognosis associated with advanced disease. Management remains challenging, especially in resource‐limited settings, where delayed presentation and restricted access to diagnostic and therapeutic modalities further compromise outcomes. Increased awareness, early diagnosis, and improved access to multidisciplinary care are essential to enhance survival in patients with this rare but highly lethal malignancy. Author Contributions John Lugata: conceptualization, investigation, writing – original draft, methodology, validation, visualization, writing – review and editing, data curation. Onesmo Mrosso: conceptualization, investigation, methodology, writing – review and editing, data curation. Tecla Lyamuya: conceptualization, investigation, writing – original draft, writing – review and editing, methodology. Jasmine E. Arrington: methodology, investigation, writing – original draft, writing – review and editing, supervision. Elizabeth Skinner: methodology, writing – original draft, writing – review and editing, supervision. Bariki Mchome: writing – original draft, methodology, writing – review and editing, validation, supervision. Eusebious Maro: conceptualization, writing – original draft, investigation, validation, methodology, writing – review and editing, formal analysis, supervision. Alex Mremi: conceptualization, writing – original draft, writing – review and editing, methodology, supervision. Funding The authors have nothing to report. Consent Written informed consent for the publication of clinical details and images was obtained from the patient. A copy of the consent is available for review by the chief editor of this journal. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors would like to thank the patient for her permission to use her medical information for shared learning purposes in this publication. We equally appreciate the contributions, support, and input from Dr. Julius Kaleshu and Dr. Peter Mbinda in this work. Data Availability Statement There is no data generated from this study. References Associated Data Data Availability Statement There is no data generated from this study.